A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes

Blood

Volumn 95, Issue 6, 2000, Pages 2098-2103

  Löffler, Anja ^b   Kufer, Peter ^a   Lutterbüse, Ralf ^b   Zettl, Florian ^b   Daniel, Peter T ^b   Schwenkenbecher, Jan M ^b   Riethmüller, Gert ^b   Dörken, Bernd ^b   Bargou, Ralf C ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNOLOGY; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0343415665     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.6.2098     Document Type: Article

References (45)

1. Urba WJ, Duffey PL, Longo DL. Treatment of patients with aggressive lymphomas: an overview. J Natl Cancer Inst Monogr. 1990;10:29-37.
2. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997; 336:1290-1297.
3. Fisher RI. Treatment of aggressive non-Hodgkin lymphomas. Lessons from the past 10 years. Cancer. 1994;74(9 suppl):2657-2661.
4. Haagen IA, van de Griend R, Clark M, Geerars A, Bast B, de Gast B. Killing of human leukaemia/ lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19). Clin Exp Immunol. 1992;90:368-375.
5. Uckun FM, Ledbetter JA. Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci U S A. 1988; 85:8603-8607.
6. Bohlen H, Hopff T, Manzke O, et al. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood. 1993;82:1803-1812.
7. Bohlen H, Manzke O, Patel B, et al. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res. 1993;53:4310-4314.
8. Bohlen H, Manzke O, Titzer S, et al. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3 × CD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Cancer Res. 1997;57:1704-1709.
9. Haagen IA, de Lau WB, Bast BJ, Geerars AJ, Clark MR, de Gast BC. Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 × CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol Immunother. 1994;39:391-396.
10. Haagen IA, Geerars AJ, de Lau WB, et al. Killing of autologous B-lineage malignancy using CD3 × CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood. 1994; 84:556-563.
11. Haagen IA, Geerars AJ, de Lau WB, Bast BJ, de Gast BC. The efficacy of CD3 × CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood. 1995;85:3208-3212.
12. Haagen IA. Performance of CD3 × CD19 bispecific monoclonal antibodies in B cell malignancy. Leuk Lymphoma. 1995;19:381-393.
13. Weiner GJ, De Gast GC. Bispecific monoclonal antibody therapy of B-cell malignancy. Leuk Lymphoma. 1995;16:199-207.
14. Csoka M, Strauss G, Debatin KM, Moldenhauer G. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3 × CD19 bispecific antibody. Leukemia. 1996;10:1765-1772.
15. Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA. 1986;83:1453-1457.
16. Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cylotoxic T lymphocytes. Eur J Immunol. 1987;17:105-111.
17. Nitta T, Sato K, Yagita H, Okumura K, Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet. 1990;335:368-371.
18. Kroesen BJ, ter Haar A, Spakman H, et al. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother. 1993;37:400-407.
19. Zhu Z, Lewis GD, Carter P. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 over-expressing tumor cells. Int J Cancer. 1995;62: 319-324.
20. Wallender WD, Ferreira ST, Voss EJ, Coelho ST. Inter-active-site distance and solution dynamics of a bivalent-bispecific single-chain antibody molecule. Biochemistry. 1994;33:10,100-10,108.
21. Mallender WD, Voss EJ. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem. 1994;269:199-206.
22. Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol. 1992;148:1547-1553.
23. Gruber M, Schodin BA, Wilson ER, Kranz DM. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol. 1994;152:5368-5374.
24. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A. 1995;92:7021-7025.
25. Kufer P, Mack M, Gruber R, Lutterbuse R, Zettl F, Riethmuller G. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother. 1997;45:193-197.
26. Mack M, Gruber R, Schmidt S, Riethmuller G, Kufer P. Biologic propertes of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol. 1997;158:3965-3970.
27. Pezzutto A, Dorken B, Rabinovitch PS, Ledbetler JA, Moldenhauer G, Clark EA. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol. 1987;138:2793-2799.
28. Orlandi R, Gussow DH, Jones PT, Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci USA. 1989;86:3833-3837.
29. Dübel S, Breitling F, Fuchs P, et al. Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J Immunol Methods. 1994;175:89-95.
30. Traunecker A, Lanzavecchia A, Karjalainen K. Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J. 1991;10:3655-3659.
31. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
32. Bohlen H, Manzke O, Engert A, et al. Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation. J Immunol Methods. 1994;173:55-62.
33. Daniel PT, Kroidl A, Kopp J, et al. Immunotherapy of B-cell lymphoma with CD3 × 19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood. 1998;92:4750-4757.
34. Demanet C, Brissinck J, Moser M, Leo O, Thielemans K. Bispecific antibody therapy of two murine B-cell lymphomas. Int J Cancer Suppl. 1992; 7:67-68.
35. De Gast GC, Van Houten AA, Haagen IA, et al. Clinical experience with CD3 × CD19 bispecific antibodies in patients with B cell malignancies. J Hematother. 1995;4:433-437.
36. Weiner GJ, Kostelny SA, Hillstrom JR, et al. The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J Immunol. 1994;152: 2385-2392.
37. Andersen PM, Crist W, Hasz D, Carroll AJ, Myers DE, Uckun FM. G19.4(alpha CD3) × B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood. 1992;80: 2826-2834.
38. Kipriyanov SM, Moldenhauer G, Strauss G, Little M. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer. 1998;77:763-772.
39. Hartmann F, Renner C, Jung W, et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood. 1997;89: 2042-2047.
40. Valone FH, Kaufman PA, Guyre PM, et al. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematother. 1995;4: 471-475.
41. Valone FH, Kaufman PA, Guyre PM, et al. Phase la/lb trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/ neu. J Clin Oncol. 1995;13:2281-2292.
42. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 1995;87:1463-1469.
43. Bolhuis RL, Lamers CH, Goey SH, et al. Adoptive immunotherapy of ovarian carcinoma with bsMAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl. 1992;7:78-81.
44. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402-3408.
45. Davis T, Levy R, White CA, et al. Retreatments with Rituxan (rituximab, IDEC-C2B8) have significant efficacy, do not cause HAMA and are viable minimally toxic alternatives in relapsed or refractory non-Hodgkin's lymphoma (NHL). Blood. 1997;90, 10(Suppl 1, Part 1):509a. Abstract 2269.